# High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

> **NCT00002818** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 15 (actual)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** cytarabine
- **DRUG:** deoxycytidine

## Key facts

- **NCT ID:** NCT00002818
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-02
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002818, "High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00002818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*